OnKure Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OnKure Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 10, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.52M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($52.67M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($35.31M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($51.96M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($39.77M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($19.47M) | Mar 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($62.95M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($54.39M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($36.93M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($53.85M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($39.82M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($19.55M) | Mar 23, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.26M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $43.80M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $32.12M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $37.71M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $28.17M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $15.94M | Mar 23, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($51.83M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($51.12M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($34.55M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($47.36M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($37.98M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($18.54M) | Mar 23, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $52.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $246.0K | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $346.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $198.0K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $24.0K | Mar 23, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.12M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $114.91M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $35.73M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $108.18M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $154.02M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $55.22M | Mar 23, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.93M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $11.08M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $7.75M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $8.21M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.81M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $4.62M | Mar 23, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.18M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $103.83M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($101.84M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($54.42M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2021 | $147.21M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($42.12M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | ($23.13M) | Mar 23, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($214.24M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($154.72M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($102.05M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($136.68M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($84.73M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($44.96M) | Mar 23, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.05M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $110.76M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $29.88M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $19.93M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $124.66M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $53.61M | Mar 23, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (15) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (124) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | (9) | Mar 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (15) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (124) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | (9) | Mar 23, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 33.42M | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | 24.70M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 24.46M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 2.05M | Mar 23, 2022 |